Get the Stockscreener App
40.98
9.32%
-4.21
After Hours:
41.30
0.32
+0.78%
Guardant Health Inc stock is traded at $40.98, with a volume of 9.12M.
It is down -9.32% in the last 24 hours and down -21.25% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$45.19
Open:
$44.86
24h Volume:
9.12M
Relative Volume:
3.97
Market Cap:
$5.08B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-9.6651
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
-9.91%
1M Performance:
-21.25%
6M Performance:
-12.77%
1Y Performance:
+16.65%
1-Day Range:
$40.53
$46.25
1-Week Range:
$40.53
$46.25
52-Week Range:
$20.14
$53.42
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
40.98 | 5.60B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
467.68 | 180.17B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
197.16 | 146.07B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
534.31 | 46.01B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
114.81 | 33.53B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
185.86 | 32.56B | 15.50B | 1.33B | 2.16B | 7.34 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference - Yahoo Finance
Guardant Health Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Earnings - Benzinga
Scotiabank raises Guardant Health stock price target to $60 on strong results - Investing.com Australia
Guardant Health Beat Wall Street Expectations And Raised Its Outlook - Finimize
Guardant Health 2025 Q2 Earnings Mixed Results as Net Loss Narrows - AInvest
Guardant Health (GH) Q2 Revenue Up 31% - The Motley Fool
Guardant Health Inc (GH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... - Yahoo Finance
Stocks To Watch: Guardant Health Sees Relative Strength Rating Jump To 85 - Investor's Business Daily
Guardant Health: Q2 Earnings Snapshot - CTPost
What is the risk reward ratio of investing in Guardant Health Inc. stockRetirement Planning Tracker To Watch Now - jammulinksnews.com
Guardant Health (GH): Navigating Growth, Margins, and Valuation in a Competitive Healthcare Innovation Landscape - AInvest
Earnings call transcript: Guardant Health beats Q2 2025 forecasts, shares rise By Investing.com - Investing.com South Africa
Earnings call transcript: Guardant Health beats Q2 2025 forecasts, shares rise - Investing.com Canada
Guardant Health (GH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Guardant Health (NASDAQ:GH) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales - Yahoo Finance
Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Guardant Health Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Guardant Health Q2 2025 slides: revenue up 31%, raises full-year guidance - Investing.com India
Guardant Health soars on strong Q2 results, raises 2025 outlook By Investing.com - Investing.com India
Guardant Health soars on strong Q2 results, raises 2025 outlook - Investing.com Australia
Guardant Health earnings beat by $0.28, revenue topped estimates - Investing.com Canada
Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance - Yahoo Finance
Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+ - Enidnews.com
What makes Guardant Health Inc. stock price move sharplyHigh Growth Low Risk Stock Selection Gets Analyst Nod - metal.it
New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer - Yahoo Finance
Guardant Health's Q2 Earnings: A Critical Inflection Point for Precision Oncology Growth - AInvest
Guardant Health (GH) Q2 Earnings: What To Expect - Yahoo Finance
Should I hold or sell Guardant Health Inc. stock in 2025Beginner Investor Alerts For Fast Growth - jammulinksnews.com
What catalysts could drive Guardant Health Inc. stock higher in 2025Invest smarter and grow your wealth faster - jammulinksnews.com
Why is Guardant Health Inc. stock attracting strong analyst attentionUnlock your portfolio’s full growth potential - jammulinksnews.com
Guardant Health: Top-Line Strength Clear, Profitability Still Elusive - Seeking Alpha
Guardant Health GH 2025Q2 Earnings Preview Upside Potential on Revised Revenue Guidance - AInvest
What is Guardant Health Inc. company’s growth strategyUnlock your trading potential today - jammulinksnews.com
Lobbying Update: $241,000 of GUARDANT HEALTH lobbying was just disclosed - Quiver Quantitative
What are the latest earnings results for Guardant Health Inc.Extraordinary earning power - jammulinksnews.com
What institutional investors are buying Guardant Health Inc. stockUnlock expert market analysis instantly - jammulinksnews.com
How volatile is Guardant Health Inc. stock compared to the marketBuild a portfolio for long-term financial success - jammulinksnews.com
What are Guardant Health Inc. company’s key revenue driversCapitalize on emerging market sectors - jammulinksnews.com
Will Guardant Health Inc. stock split in the near futureROI Driven Alerts - metal.it
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics - Benzinga
Guardant Health Enrolls First Patient in NCI Vanguard Study for Multi-Cancer Detection Test - MSN
What drives Guardant Health Inc. stock priceConsistent wealth multiplication - PrintWeekIndia
What analysts say about Guardant Health Inc. stockTremendous growth potential - PrintWeekIndia
Is Guardant Health Inc. a good long term investmentDynamic growth stocks - PrintWeekIndia
1 Healthcare Stock with Solid Fundamentals and 2 We Avoid - Yahoo Finance
10 Best Mid Cap Pharma Stocks to Buy - Insider Monkey
Colonoscopies are no fun. These at-home colon cancer screenings offer a shortcut. - Business Insider
Guardant Health (NASDAQ:GH investor five-year losses grow to 44% as the stock sheds US$228m this past week - Yahoo Finance
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):